Mitral Valve Regurgitation
Conditions
Keywords
Mitral Regurgitation, Mitral valve repair, Mitral annuloplasty, Adjustable annuloplasty
Brief summary
KALIOS is indicated for the surgical treatment of mitral regurgitation by mitral valve repair.It is intended for mitral valve repair using conventional open heart or minimally invasive techniques. The KALIOS device is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3 The primary objective of this clinical investigation is to assess the safety and effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) The secondary objectives are to investigate the effects of KALIOS for the surgical treatment of Mitral Regurgitation on cardiac function and on patient functional status This clinical trial is prospective, non-randomized, single arm, multicentric & international. Up to 100 patients are expected to be enrolled to obtain 62 evaluable patients at one year,presenting with primary (degenerative) or secondary (functional) mitral valve regurgitation and who are candidate to a mitral valve repair.
Interventions
DEVICEKalios Implant
KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
Sponsors
Kephalios
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Patients must meet ALL the following inclusion criteria : 1. with primary or secondary mitral regurgitation recorded by TTE and confirmed during TEE where surgery for mitral valve repair is required with indications consistent with AHA/ACC and ESC/EACTS guidelines : 1. primary (degenerative) : severe MR grade parameters (R Vol and EROA measured by PISA methods): * EROA regurgitant \>60 ml and * Vena contracta width \> 7mm and * Regurgitant fraction \>50% 2. Secondary (functional) : severe MR (EROA ≥30 mm²; R Vol \> 30ml) may differ from the primary MR and are based on the prognostic value of these thresholds to predict the poor outcome, or for patients undergoing CABG 2. with LVEF ≥ 30% 3. in satisfactory condition, based on the physical examination and investigator's experience, with a life expectancy above one year after the intervention 4. with or without concomitant procedures as: CABG, other valve repair/replacement, pacemaker implantation, exclusion of left appendage (with device or surgically) and Maze (or PVI) procedure 5. willing to sign the informed consent; 6. able and willing to comply with all clinical investigation requirements, including the required study follow-up visits
Exclusion criteria
* Patients will be excluded if ANY of the following conditions are present: 1. of age \< 21 years; 2. with echocardiographic measurements predicting SAM 1. LVEDD \< 45 mm 2. C-Sd \< 25mm (distance from the septum to the mitral valve coaptation point) 3. Basal-IVDd \> 15 mm 4. aorto-mitral angle \< 120° 5. pre-repair posterior leaflet height \> 15 mm 3. with cardiogenic shock; 4. with active endocarditis (or having had active endocarditis in the last three months); 5. with active myocarditis; 6. with heavily calcified mitral annulus; 7. with mitral stenosis; 8. unable to take anticoagulation medications; 9. with a known untreatable allergy to contrast media or nickel; 10. with a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy shorter than 1 year, or for whom the implant of the device produces an unacceptable increase of risk; 11. with contraindication to transoesophageal echocardiography; 12. with contraindication to cardiopulmonary bypass; 13. who are pregnant or breast-feeding women; 14. involved in any other clinical investigation for drugs or devices; 15. unable to understand and sign the ICF in absence of legal protection; 16. unable to read and write;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) | At 1 year | Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment) |
| Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)Regurgitation with optional intra-operative and/or post-operative adjustment(s) | At 1 year | Incidence of Major Adverse Cardiac Events (MACE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the effectiveness of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s) at each follow up | at 1, 3 6, 24, 36, 48 and 60 months | Absence of Mitral Regurgitation of grade \> 2 (through echographic assessment) |
| Assessment of the adjustment functionality of the device | immediately after annuloplasty, at 1, 3, 6, 12, 24, 36, 48 and 60 months | Assessment of mitral leaflets coaptation (through echographic assessment) |
| Assessment of the safety of KALIOS for the surgical treatment of Mitral Regurgitation with optional intra-operative and/or post-operative adjustment(s)at each follow up | at 1, 3, 6, 24, 36, 48 and 60 months | Incidence of Major Adverse Cardiac Events (MACE) |
Countries
Austria, Germany, Italy, Switzerland
Contacts
Primary ContactMichel Finance
Outcome results
None listed